1992
Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside
Chatterjee D, Chakraborty M, Anderson G. Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside. Brain Research 1992, 583: 31-44. PMID: 1324094, DOI: 10.1016/s0006-8993(10)80007-1.Peer-Reviewed Original ResearchMeSH KeywordsAmino AcidsAnimalsAntibodies, MonoclonalBromodeoxyuridineBucladesineCatecholaminesCell DifferentiationCell DivisionCell LineDNA ReplicationElectrophoresis, Gel, Two-DimensionalElectrophoresis, Polyacrylamide GelFluorescent Antibody TechniqueG(M3) GangliosideGangliosidesKineticsMethionineMiceModels, BiologicalMolecular WeightNeoplasm ProteinsNeuroblastomaSerotoninThymidineConceptsNeuro-2a cellsTotal cellular proteinProtein kinase A (PKA) inhibitorProtein kinase C activityInhibitors of PKCKinase C activityNeuro-2a neuroblastoma cellsCellular proteinsCellular differentiationCell surface gangliosidesElevated intracellular cAMP levelsDifferentiated cellsIntracellular cAMP levelsCyclase activityMode of actionGi proteinsProteinPKCSurface gangliosidesC activityDifferentiationAdenylate cyclase activityNeuroblastoma cellsA inhibitorsGM2 ganglioside
1984
Whole blood serotonin and tryptophan levels in Tourette's disorder: Effects of acute and chronic clonidine treatment
Leckman J, Anderson G, Cohen D, Ort S, Harcherik D, Hoder E, Shaywitz B. Whole blood serotonin and tryptophan levels in Tourette's disorder: Effects of acute and chronic clonidine treatment. Life Sciences 1984, 35: 2497-2503. PMID: 6595491, DOI: 10.1016/0024-3205(84)90435-1.Peer-Reviewed Original ResearchConceptsChronic clonidine treatmentClonidine treatmentTourette's disorder patientsWhole blood serotoninDisorder patientsTourette's disorderBlood serotoninTryptophan levelsMean differenceChronic treatmentAcute doseNormal controlsMean increaseClonidinePatientsDisordersMode of actionTreatmentSignificant differencesSerotoninBaseline conditionsLevelsDifferencesDose